These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 31365790)

  • 1. The influence of microenvironment on tumor immunotherapy.
    Zhang J; Shi Z; Xu X; Yu Z; Mi J
    FEBS J; 2019 Nov; 286(21):4160-4175. PubMed ID: 31365790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for Checkpoint Inhibition.
    Weber JS
    Am Soc Clin Oncol Educ Book; 2017; 37():205-209. PubMed ID: 28561695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for Immunotherapy: Current Developments and Challenges.
    Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting galectins in T cell-based immunotherapy within tumor microenvironment.
    Jin QY; Li YS; Qiao XH; Yang JW; Guo XL
    Life Sci; 2021 Jul; 277():119426. PubMed ID: 33785342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue Site and the Cancer Immunity Cycle.
    Horton BL; Fessenden TB; Spranger S
    Trends Cancer; 2019 Oct; 5(10):593-603. PubMed ID: 31706507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
    Omar HA; El-Serafi AT; Hersi F; Arafa EA; Zaher DM; Madkour M; Arab HH; Tolba MF
    FEBS J; 2019 Sep; 286(18):3540-3557. PubMed ID: 31306553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting innate sensing in the tumor microenvironment to improve immunotherapy.
    Liu Z; Han C; Fu YX
    Cell Mol Immunol; 2020 Jan; 17(1):13-26. PubMed ID: 31844141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Mechanisms of Inhibitory Immune Checkpoint Receptors Expression.
    Curdy N; Lanvin O; Laurent C; Fournié JJ; Franchini DM
    Trends Cell Biol; 2019 Oct; 29(10):777-790. PubMed ID: 31378317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial Cancer Immunotherapies.
    Hellmann MD; Friedman CF; Wolchok JD
    Adv Immunol; 2016; 130():251-77. PubMed ID: 26923003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment.
    Lv D; Fei Y; Chen H; Wang J; Han W; Cui B; Feng Y; Zhang P; Chen J
    Front Immunol; 2024; 15():1340702. PubMed ID: 38690275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic checkpoints and novel approaches for immunotherapy against cancer.
    Li Y; Tang J; Jiang J; Chen Z
    Int J Cancer; 2022 Jan; 150(2):195-207. PubMed ID: 34460110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cell surface proteoglycans in cancer immunotherapy.
    Espinoza-Sánchez NA; Götte M
    Semin Cancer Biol; 2020 May; 62():48-67. PubMed ID: 31336150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of immunotherapy.
    Suzuki S; Ishida T; Yoshikawa K; Ueda R
    Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
    Garris CS; Luke JJ
    Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
    Rivadeneira DB; Delgoffe GM
    Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
    Tsai HF; Hsu PN
    J Biomed Sci; 2017 May; 24(1):35. PubMed ID: 28545567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
    Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
    Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.
    Wei F; Wang D; Wei J; Tang N; Tang L; Xiong F; Guo C; Zhou M; Li X; Li G; Xiong W; Zhang S; Zeng Z
    Cell Mol Life Sci; 2021 Jan; 78(1):173-193. PubMed ID: 32654036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.